Study to Evaluate the Safety and Efficacy of Vesatolimod in Antiretroviral Treated Human Immunodeficiency Virus (HIV-1) Infected Controllers

Completed · Phase 1 · Has a placebo group

Conditions studied: HIV-1 Infection

In brief

The primary objective of this study is to evaluate the safety and tolerability of a 10-dose regimen of vesatolimod in HIV-1 infected controllers on antiretroviral treatment (ART) and during analytical treatment interruption (ATI) following vesatolimod dosing.

Key facts

Study ID

NCT03060447

Run by

Gilead Sciences

People needed

25

Starts

2017-05-09

Expected to finish

2020-02-13

Last updated by the study team

2021-04-21

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Mills Clinical Research — Los Angeles, California, United States
• Zuckerberg San Francisco General — San Francisco, California, United States
• Midway Immunology & Research Center — Ft. Pierce, Florida, United States
• Orlando Immunology Center — Orlando, Florida, United States
• Central Texas Clinical Research — Austin, Texas, United States
• Peter Shalit, MD — Seattle, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.